Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC

New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more. Join us to hear the latest options and have your questions answered in this webinar.
For more information about SHARE, visit our website at sharecancersupport.org or call our Helpline at 844.ASK.SHARE (844.275.7427).